Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Dec 31;20(1):2341456.
doi: 10.1080/21645515.2024.2341456. Epub 2024 Apr 22.

Immunogenicity and safety of live attenuated and recombinant/inactivated varicella zoster vaccines in people living with HIV: A systematic review

Valentina Carta  1 , Lucia Mangeri  1 , Giorgio Tiecco  2 , Emanuele Focà  2 , Eugenia Quiros-Roldan  2 , Maria Antonia De Francesco  3
Affiliations

Immunogenicity and safety of live attenuated and recombinant/inactivated varicella zoster vaccines in people living with HIV: A systematic review

Valentina Carta et al. Hum Vaccin Immunother. .

Abstract

Few papers focus their attention on VZV vaccination effectiveness among people living with HIV (PLWH). Flanking the live attenuated vaccine (VZL) available, a newly recombinant vaccine (RZV) was recently introduced and approved for HZ prevention among adults. PLWH represents a population on which a particular attention should be applied, in order to guarantee the vaccine efficacy and safety. We performed a literature search in USNLM, PubMed, PubMed Central, PMC and Cochrane Library. From all the publications found eligible, data were extracted and processed per population, vaccine type, immunogenicity and ADRs. The review of the 13 included studies shows that both RZV and VZL are immunogenic and have an acceptable safety profile in adults and children living with HIV. However, given the lack of research available about vaccine efficacy in preventing VZV and HZ in PLWH, additional studies need to be performed, in order to achieve a full completeness of data.

Keywords: Vaccine; herpes zoster; immunogenicity; safety; varicella.

PubMed Disclaimer

Conflict of interest statement

No potential conflict of interest was reported by the author(s).

Figures

Figure 1.
Figure 1.
Adapted PRISMA 2020 Flow Diagram.
See this image and copyright information in PMC

References

    1. Gabutti G, Bolognesi N, Sandri F, Florescu C, Stefanati A.. Varicella zoster virus vaccines: an update. Immunotargets Ther. 2019;8:15–16. doi:10.2147/ITT.S176383. - DOI - PMC - PubMed
    1. Gershon AA, Breuer J, Cohen JI, Cohrs RJ, Gershon MD, Gilden D, Grose C, Hambleton S, Kennedy PGE, Oxman MN, et al. Varicella zoster virus infection. Nat Rev Dis Primers. 2015;1(1):15016. doi:10.1038/nrdp.2015.16. - DOI - PMC - PubMed
    1. Abendroth A, Arvin AM, Moffat JF. Varicella-zoster virus. Springer Science & Business Media; 2010.
    1. Marin M, Guris D, Chaves SS, Schmid S, Seward JF. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practice (ACIP). Vol. 56, MMWR Recomm Rep; 2007. pp. 1–40. - PubMed
    1. World Health Organization . Varicella and herpes zoster vaccines: WHO position Paper. Wkly Epidemiol Rec. 2014;25:265. - PubMed

Publication types

MeSH terms